<DOC>
	<DOCNO>NCT02703571</DOCNO>
	<brief_summary>Phase Ib dose escalation advance solid tumor identify dose Phase II dose expansion advance metastatic pancreatic cancer KRAS-mutant colorectal cancer . Open-label , nonrandomized .</brief_summary>
	<brief_title>Study Safety Efficacy Ribociclib Trametinib Patients With Metastatic Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<criteria>Inclusion Criteria ( All ) : Written inform consent must Patient histologically and/or cytologically confirm malignancy : Phase I : • Patients advance metastatic solid tumor fail least one prior line systemic antineoplastic therapy advance set without standard care treatment option available ; Phase II : Advanced metastatic pancreatic adenocarcinoma fail least one prior systemic antineoplastic therapy advance set Advanced metastatic KRASmutant CRC fail least two prior systemic antineoplastic therapy advance set without standard care treatment option available . Testing KRAS mutation patient CRC use locally approve diagnostic kit use eligibility . Phase II : patient must measurable disease Patient ECOG performance status 0 1 . Patient adequate bone marrow organ function Patient must specify laboratory value within normal limit correct within normal limit supplement first dose study medication Cycle 1 Day 1 : Standard 12lead ECG value define Phase II : • Patient receive prior treatment MEK inhibitor CDK4/6 inhibitor . Phase I Phase II : Patient know hypersensitivity study drug excipients ribociclib trametinib . Patient concurrently use anticancer therapy . Patient receive radiotherapy ≤ 4 week limited field radiation palliation ≤ 2 week prior Cycle 1 Day 1 Prior systemic anticancer treatment within 21 day prior Cycle 1 Day 1 Prior therapy anthracyclines cumulative dos 450 mg/ m2 doxorubicin 900 mg/m2 epirubicin . Patient currently receive warfarin coumarin derive anticoagulant Patient concurrent malignancy malignancy within 3 year prior Cycle 1 Day 1 , exception adequately treat basal squamous cell carcinoma curatively resect cervical cancer . Patients central nervous system ( CNS ) involvement Patient impairment GI function GI disease may significantly alter absorption study drug History interstitial lung disease pneumonitis . Clinically significant , uncontrolled heart disease and/or cardiac repolarization abnormality Patient currently receive strong inducer inhibitor CYP3A4/5 and/or Substances narrow therapeutic window predominantly metabolize CYP3A4/5 discontinue 7 day prior Cycle 1 Day 1 : Patient currently receive receive systemic corticosteroid ≤ 2 week prior start study drug , fully recover side effect treatment . History retinal vein occlusion ( RVO ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Trametinib</keyword>
	<keyword>Ribociclib</keyword>
	<keyword>LEE011</keyword>
	<keyword>TMT212</keyword>
	<keyword>advanced solid tumor</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>KRAS-mutant colorectal cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>advanced pancreatic cancer</keyword>
	<keyword>metastatic pancreatic cancer</keyword>
</DOC>